• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 20th December 2012

Spotlight on OHE: Measurement and Valuation of Health Using PROMs

The OHE continues to play a central role in the development and use of patient-reported outcomes measures (PROMs). The last quarter of 2012 was characteristically busy. The OHE continues to play a central role in the development and use of patient-reported…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Training for the data collection phase of the EQ-5D-5L Value Set for England study

The OHE continues to play a central role in the development and use of patient-reported outcomes measures (PROMs). The last quarter of 2012 was characteristically busy.

The OHE continues to play a central role in the development and use of patient-reported outcomes measures (PROMs). The last quarter of 2012 was characteristically busy.

In September, OHE’s Prof Nancy Devlin, chair of the EuroQol Group’s Executive Committee, gave a presentation at the Group’s Scientific Plenary meeting in Rotterdam, setting out the scientific direction for the Group for the coming years. Her presentation, summarised recent developments in EQ-5D instruments for measuring health and methods for valuing health states. She noted that much of the research agenda for the Group in recent years has been dominated by the requirements of economic evaluation and cost effectiveness analysis. Nancy outlined plans for six new workings groups that will pursue specific research agendas—on value sets, valuation methodology, establishing of a EuroQol data archive, EQ-5D in children, EQ-5D in large scale health applications, and use of EQ-5D outside the health care sector.  Nancy was also co-author of a paper presented at the plenary: Gutacker, N., Bojke, C., Daidone, S., Devlin, N. and Street, A. (forthcoming) Hospital variation in patient-reported outcomes at the level of EQ-5D dimensions: Evidence from England. Medical Decision Making.

At ISPOR in November, Nancy chaired a symposium where she presented the EuroQol Group’s scientific agenda and introduced plans for new areas of methodological research. This includes in particular experimental work on the potential use of “bolt on” dimensions for the EQ-5D.  The symposium discussed the conceptual and empirical challenges involved in developing and valuing these bolt ons.

In October, Nancy was the keynote speaker at a Canadian conference on PROMs organised by the Health Quality Council of Alberta, the Institute of Health Economics and Alberta Health Services. Her presentation, NHS Experience of the EQ-5D as an Outcomes Measure, discussed the rationale for the PROMs programme and provided an overview of the various uses of the EQ-5D in England—for example by NICE in health technology assessment, in population surveys and in the English NHS PROMS program. The presentation also reviewed how EQ-5D data are collected, analysed and used in the UK to inform decisions by health care providers, payers and patients.

In November, the UK King’s Fund held a conference on PROMs. Nancy’s presentation, Analysis of EQ-VAS and EQ-5D Profile Data from PROMs, explained that while the analysis of index-weighted EQ-5D profiles is useful, use of EQ-5D data should not be restricted to analysis of index-weighted profiles. The reasons include: (a) index weighting obscures relevant information on the underlying health problems  that drive index-weighted scores, (b) hospital performance varies across dimensions, which has implications for understanding where improvements in performance are possible, (c) patients’ “raw” EQ-5D profile data can reveal important information about relevant patient subgroups and (d) The EQ-VAS provides the patients’ own perspective on overall health whereas index weighting reflects the preferences of the general public. The presentation drew, in part, on new results from a paper to be presented at the Health Economics Study Group in January 2013 by David Parking, Nancy Devlin and Feng, What determines the shape of an EQ-5D Index distribution?

Training for the data collection phase of the EQ-5D-5L Value Set for England study

In October and November, OHE’s Prof Nancy Devlin and Koonal Shah, Brendan Mulhern from Sheffield University, and staff from Ipsos Mori ran a series of all-day workshops in London and Leeds that marked the start of the data collection phase of the EQ-5D-5L Value Set for England study. (See our earlier blog post for additional information.) Ipsos Mori interviewers were trained in the use of the computer-aided personal interview techniques developed by the EuroQol Group for use in this and similar studies currently underway around the world. In 2013, this study will produce a value set that will facilitate use of the five-level version of the EQ-5D in a wide range of applications, including clinical trials, observational studies, population health surveys and the PROMs programme. Funded by NIHR Policy Research Programme grant, the study is led by Prof Nancy Devlin and Prof Ben van Hout and involves OHE’s Dr Yan Feng.

OHE and Sheffield University also have been awarded grants from the EuroQol Foundation and the Chief Scientist Office of the Scottish Government to undertake data collection in Wales, Northern Ireland and Scotland to produce an EQ-5D-5L value set for all of the UK.

In November, the EuroQol Group and NICE International collaborated in presenting an EQ-5D workshop at the China National Health Development Research Center (CNHDRC) in Beijing. The workshop was chaired by Francis Ruiz of NICE International and Prof Zhao Kun from the CNHDRC. Prof Nancy Devlin and Prof Jan van Busschbach of Erasmus University presented the programme on behalf of the EuroQol Group. Nancy’s presentations focused three topics: the development of the EQ-5D-5L, the use of EQ-5D in decision making and the use of EQ-5D in health service performance management in the NHS PROMs programme.

For more information on OHE’s PROMs-related activities, please contact Prof Nancy Devlin.

  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes
  • Spotlight on OHE

Related News

  • News
  • November 2021

Opportunity Cost in Health Care: a Favourite Research Topic for OHE

Read more
  • News
  • May 2020

OHE Awarded Independent Research Organisation (IRO) Status by UKRI

Read more
  • News
  • February 2019

OHE Response to Public Consultation on NICE Principles

Read more
  • News
  • December 2018

OHE Achievements in 2018

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!